MBF-118 / Medibiofarma - LARVOL DELTA

Safety and Efficacy of MBF-118 in Patients with Crohn Disease (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: Medibiofarma S.L. | Recruiting ➔ Completed

Trial completion • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease

Safety and Efficacy of MBF-118 in Patients With Crohn Disease (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Medibiofarma S.L. | Phase classification: P2a ➔ P2 | Trial completion date: Apr 2024 ➔ Nov 2024 | Trial primary completion date: Apr 2024 ➔ Sep 2024

Phase classification • Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease

Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Medibiofarma S.L. | Active, not recruiting ➔ Completed

Trial completion • Oncology

Safety and Efficacy of MBF-118 in Patients With Crohn Disease (clinicaltrials.gov) - P2a | N=10 | Recruiting | Sponsor: Medibiofarma S.L.

New P2a trial • Crohn's disease • Fibrosis • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease

Study to Assess the Safety and Tolerability of MBF-118 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Medibiofarma S.L.

New P1 trial • Oncology

Medibiofarma Receives Funding from the Crohn's & Colitis Foundation to Support Development of a New Antifibrotic Therapy for Inflammatory Bowel Disease (BioSpace) - "Medibiofarma...announced receipt of funding from the Crohn's & Colitis Foundation's IBD Ventures program today to support development of MBF-118, a first-in-class, oral therapy for inflammatory bowel disease (IBD). MBF-118 is a patented new chemical entity that acts as a partial agonist of PPAR and has both anti-fibrotic and anti-inflammatory properties. The therapy addresses a common complication of IBD: intestinal fibrosis, an excessive accumulation of scar tissue in the intestinal wall, leading to stricture formation, which is a narrowing of part of the intestine wall due to scar tissue resulting in severe obstructions."

Financing • Inflammatory Bowel Disease